secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001213900-23-051347
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma appoints Dr. Uttam Patil as CEO after Dr. Howard Doong resigns
-----------------------------------------------------------------------------

- Dr. Howard Doong resigned as CEO effective June 21, 2023; no disagreement with Company operations.
- Board appointed Dr. Uttam Yashwant Patil as CEO and President effective June 23, 2023.
- Dr. Patil also serves as COO and Scientific Officer of subsidiary BioKey since May 2023.
- New employment agreement provides one-year term, salary paid in stock options, and severance in stock shares.
- He holds a Ph.D. in Chemistry from National Tsing Hua University and previously served as post-doctoral fellow at NTNU.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/0001213900-23-051347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390023051347/ea180822-8k_abvcbiopharm.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-051347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer